{ "instance": { "vrax-20220331.htm": { "axisCustom": 0, "axisStandard": 19, "contextCount": 175, "dts": { "calculationLink": { "local": [ "vrax-20220331_cal.xml" ] }, "definitionLink": { "local": [ "vrax-20220331_def.xml" ] }, "inline": { "local": [ "vrax-20220331.htm" ] }, "labelLink": { "local": [ "vrax-20220331_lab.xml" ] }, "presentationLink": { "local": [ "vrax-20220331_pre.xml" ] }, "schema": { "local": [ "vrax-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.ifrs.org/taxonomy/2021-03-24/full_ifrs/full_ifrs-cor_2021-03-24.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 434, "entityCount": 1, "hidden": { "http://www.viraxbiolabs.com/20220331": 4, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 8 }, "keyCustom": 80, "keyStandard": 171, "memberCustom": 51, "memberStandard": 19, "nsprefix": "vrax", "nsuri": "http://www.viraxbiolabs.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Revenue from contracts with customers", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomers", "shortName": "Revenue from contracts with customers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Key management compensation", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensation", "shortName": "Key management compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Income tax", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTax", "shortName": "Income tax", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - (Loss)/earnings per share", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShare", "shortName": "(Loss)/earnings per share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Inventories", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureInventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfAccountsReceivableExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Accounts receivable", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivable", "shortName": "Accounts receivable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfAccountsReceivableExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Cash and cash equivalents", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCashAndCashEquivalents", "shortName": "Cash and cash equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Stockholder's equity", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquity", "shortName": "Stockholder's equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Accounts payable and accrued liabilities", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities", "shortName": "Accounts payable and accrued liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Contingent liabilities and contingent assets", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssets", "shortName": "Contingent liabilities and contingent assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "lang": null, "name": "vrax:CurrentPrepaidExpensesAndDeposits", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Commitments", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Related party transactions", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactions", "shortName": "Related party transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Risk management overview", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverview", "shortName": "Risk management overview", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Subsequent Events", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfNumberOfShareIssuedInVariousEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - General Information and Reorganization Transactions (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsTables", "shortName": "General Information and Reorganization Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfNumberOfShareIssuedInVariousEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Revenue from Contracts with Customers (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables", "shortName": "Revenue from Contracts with Customers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "div", "vrax:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Summary of Significant Accounting Policies (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "vrax:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfReconciliationOfIncomeTaxesAtStatutoryRatesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Income tax (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxTables", "shortName": "Income tax (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfReconciliationOfIncomeTaxesAtStatutoryRatesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - (Loss)/Earnings per Share (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareTables", "shortName": "(Loss)/Earnings per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_c76abea5-e04d-4e85-b00a-d6df5925df41", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical", "shortName": "CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_c76abea5-e04d-4e85-b00a-d6df5925df41", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfInformationAboutInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Inventories (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureInventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfInformationAboutInventoriesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "div", "vrax:DisclosureOfAccountsReceivableExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfDetailedInformationAboutAccountsReceivableExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Accounts Receivable (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivableTables", "shortName": "Accounts Receivable (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "vrax:DisclosureOfAccountsReceivableExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfDetailedInformationAboutAccountsReceivableExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Cash and Cash Equivalents (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCashAndCashEquivalentsTables", "shortName": "Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Commitments (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsTables", "shortName": "Commitments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Related Party Transactions (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsTables", "shortName": "Related Party Transactions (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Risk Management Overview (Tables)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewTables", "shortName": "Risk Management Overview (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "vrax:DisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ifrs-full:NumberOfSharesIssued", "span", "p", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_6b27895b-7db6-4c78-a707-08e6e5821334", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesOutstanding", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - General Information and Reorganization Transaction - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "shortName": "General Information and Reorganization Transaction - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_0676ae8a-1257-4ebc-aece-a627d0164fcf", "decimals": "INF", "lang": null, "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_6b27895b-7db6-4c78-a707-08e6e5821334", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - General Information and Reorganization Transactions - Schedule of Number of Shares Issued (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails", "shortName": "General Information and Reorganization Transactions - Schedule of Number of Shares Issued (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfNumberOfShareIssuedInVariousEntitiesExplanatory", "div", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_79462eb5-41b6-4279-aa25-1a539ddf4062", "decimals": "INF", "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "div", "vrax:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_ee716e91-ead8-40e7-930d-8c09273574cb", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Summary of Significant Accounting Policies - Summary of Consolidated Subsidiaries (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails", "shortName": "Summary of Significant Accounting Policies - Summary of Consolidated Subsidiaries (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "div", "vrax:DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_ee716e91-ead8-40e7-930d-8c09273574cb", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:CountryOfIncorporationOrResidenceOfSubsidiary", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - CONSOLIDATED STATEMENTS OF PROFIT AND LOSS AND OTHER COMPREHENSIVE LOSS", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3", "shortName": "CONSOLIDATED STATEMENTS OF PROFIT AND LOSS AND OTHER COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_e5bc05a5-8386-4894-98d8-1a81442e6388", "decimals": "0", "lang": null, "name": "ifrs-full:CostOfSales", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "INF", "first": true, "lang": null, "name": "vrax:NumberOfReportableSegments1", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "INF", "first": true, "lang": null, "name": "vrax:NumberOfReportableSegments1", "reportCount": 1, "unique": true, "unitRef": "U_Segment", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfFunctionalAndPresentationCurrencyExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_ee716e91-ead8-40e7-930d-8c09273574cb", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfFunctionalCurrency", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Summary of Significant Accounting Policies - Functional and Presentation Currency (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "shortName": "Summary of Significant Accounting Policies - Functional and Presentation Currency (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfFunctionalAndPresentationCurrencyExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_ee716e91-ead8-40e7-930d-8c09273574cb", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DescriptionOfFunctionalCurrency", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_78a4781a-b71c-434e-93fe-11115774ae71", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Summary of Significant Accounting Policies - Disclosure of Effect of Changes in Foreign Exchange Rates (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails", "shortName": "Summary of Significant Accounting Policies - Disclosure of Effect of Changes in Foreign Exchange Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "div", "ifrs-full:DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "div", "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_78a4781a-b71c-434e-93fe-11115774ae71", "decimals": "3", "first": true, "lang": null, "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue from Contracts with Customers (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "shortName": "Revenue from Contracts with Customers - Schedule of Disaggregation of Revenue from Contracts with Customers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "div", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_0892615e-5f14-4502-bd69-d9dd5ba23f69", "decimals": "0", "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:RevenueFromContractsWithCustomers", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Revenue from Contracts with Customers - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "shortName": "Revenue from Contracts with Customers - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_555baaba-6bf7-4933-9ad9-c9466b842f27", "decimals": "2", "lang": null, "name": "ifrs-full:PercentageOfEntitysRevenue", "reportCount": 1, "unique": true, "unitRef": "U_pure", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Key Management Compensation - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "shortName": "Key Management Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Income Tax - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "shortName": "Income Tax - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_1aa9d892-b110-4b5a-ba76-bf20177d17e5", "decimals": "INF", "lang": null, "name": "vrax:ProvisionForProfitTax", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100490 - Disclosure - Income Tax - Reconciliation of Income Taxes at Statutory Rates (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails", "shortName": "Income Tax - Reconciliation of Income Taxes at Statutory Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfReconciliationOfIncomeTaxesAtStatutoryRatesTableTextBlock", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "0", "lang": null, "name": "vrax:TaxEffectOfExpectedIncomeTaxRecovery", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "vrax:NonCapitalLossesAvailableForFuturePeriod", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Income Tax - Summary of Net Deferred Tax Asset (Liability) (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails", "shortName": "Income Tax - Summary of Net Deferred Tax Asset (Liability) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "lang": null, "name": "ifrs-full:DeferredTaxAssets", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "vrax:NonCapitalLossesAvailableForFuturePeriod", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Income Tax - Summary of Temporary Differences (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails", "shortName": "Income Tax - Summary of Temporary Differences (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "div", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_216f4f5d-368e-49a3-8361-970d59fe97e7", "decimals": "0", "lang": null, "name": "vrax:NonCapitalLossesAvailableForFuturePeriod", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_0d7221c4-f539-46d0-a067-aa096277598a", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity", "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_0d7221c4-f539-46d0-a067-aa096277598a", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - (Loss)/Earnings per Share - Schedule of (Loss)/Earnings Per Share (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfLossearningsPerShareDetails", "shortName": "(Loss)/Earnings per Share - Schedule of (Loss)/Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:EarningsPerShareExplanatory", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_b0342eb2-d0fd-43a2-bddf-f944af85e9dc", "decimals": "2", "lang": null, "name": "ifrs-full:BasicEarningsLossPerShare", "reportCount": 1, "unique": true, "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "p", "vrax:DilutedEarningsPerShareTableTextBlock", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - (Loss)/Earnings per Share - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareAdditionalInformationDetails", "shortName": "(Loss)/Earnings per Share - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "vrax:DilutedEarningsPerShareTableTextBlock", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DilutedEarningsPerShareTableTextBlock", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - (Loss)/Earnings per Share - Schedule of Diluted (Loss)/Earnings Per Share (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfDilutedLossearningsPerShareDetails", "shortName": "(Loss)/Earnings per Share - Schedule of Diluted (Loss)/Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DilutedEarningsPerShareTableTextBlock", "div", "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageShares", "reportCount": 1, "unique": true, "unitRef": "U_shares", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfInformationAboutInventoriesExplanatory", "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:FinishedGoods", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Inventories - Summary of Inventories (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails", "shortName": "Inventories - Summary of Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfInformationAboutInventoriesExplanatory", "div", "ifrs-full:DisclosureOfInventoriesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:FinishedGoods", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfDetailedInformationAboutAccountsReceivableExplanatory", "div", "vrax:DisclosureOfAccountsReceivableExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_c2fab4a9-0ac8-46d2-a845-5ffeb263d9d1", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:NoncurrentTradeReceivables", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Accounts Receivable - Summary of Accounts Receivable (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails", "shortName": "Accounts Receivable - Summary of Accounts Receivable (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfDetailedInformationAboutAccountsReceivableExplanatory", "div", "vrax:DisclosureOfAccountsReceivableExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_c2fab4a9-0ac8-46d2-a845-5ffeb263d9d1", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:NoncurrentTradeReceivables", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:BalancesWithBanks", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "shortName": "Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:BalancesWithBanks", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "ifrs-full:CashEquivalents", "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:CashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Cash and Cash Equivalents - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "shortName": "Cash and Cash Equivalents - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ifrs-full:CashEquivalents", "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:CashEquivalents", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "INF", "first": true, "lang": null, "name": "vrax:AuthorizedShareCapital", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Stockholder's Equity - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "shortName": "Stockholder's Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "INF", "first": true, "lang": null, "name": "vrax:AuthorizedShareCapital", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "div", "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "shortName": "Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "div", "vrax:DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_d40dc6fd-b4b1-4615-97f6-7a1659837903", "decimals": "0", "first": true, "lang": null, "name": "vrax:CourtArbitrationAwardAgainstSuppliers", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Contingent Liabilities and Contingent Assets - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails", "shortName": "Contingent Liabilities and Contingent Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_d40dc6fd-b4b1-4615-97f6-7a1659837903", "decimals": "0", "first": true, "lang": null, "name": "vrax:CourtArbitrationAwardAgainstSuppliers", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOW", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOW", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": "0", "lang": null, "name": "ifrs-full:AdjustmentsForSharebasedPayments", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "INF", "first": true, "lang": null, "name": "vrax:NumberOfRemainingLeaseAgreement", "reportCount": 1, "unique": true, "unitRef": "U_LeaseAgreement", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Commitments - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "shortName": "Commitments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "INF", "first": true, "lang": null, "name": "vrax:NumberOfRemainingLeaseAgreement", "reportCount": 1, "unique": true, "unitRef": "U_LeaseAgreement", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "div", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Commitments - Schedule of Commitments for Minimum Lease Payments (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails", "shortName": "Commitments - Schedule of Commitments for Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "div", "ifrs-full:DisclosureOfCommitmentsExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:UndiscountedOperatingLeasePaymentsToBeReceived", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Related Party Transactions - Summary of Related Party Payables (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails", "shortName": "Related Party Transactions - Summary of Related Party Payables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_d180fd2e-85bb-4a46-a26d-611429ad9422", "decimals": "0", "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "div", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfRelatedPartyExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_4beb867b-7210-48fc-b0de-a91b7d291b9d", "decimals": "0", "lang": null, "name": "ifrs-full:AmountsPayableRelatedPartyTransactions", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:MaximumExposureToCreditRisk", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Risk Management Overview - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "shortName": "Risk Management Overview - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:MaximumExposureToCreditRisk", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_daee317f-b33d-4523-b52b-053818a2fddb", "decimals": "0", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unitRef": "U_USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Risk Management Overview - Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "shortName": "Risk Management Overview - Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "td", "tr", "table", "vrax:DisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatory", "div", "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_2c9856c0-a790-495f-b81c-312591bb4999", "decimals": "0", "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "U_CNY", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_6b27895b-7db6-4c78-a707-08e6e5821334", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "U_shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Subsequent Events - Additional Information (Details)", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory", "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_8b2f82c9-df85-4874-a97f-9aab691adc8a", "decimals": "0", "lang": null, "name": "vrax:CurrentAccountsPayableAndAccruedLiabilities", "reportCount": 1, "unique": true, "unitRef": "U_USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100070 - Disclosure - General information and reorganization transactions", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactions", "shortName": "General information and reorganization transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Critical estimates and judgments", "role": "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCriticalEstimatesAndJudgments", "shortName": "Critical estimates and judgments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "vrax-20220331.htm", "contextRef": "C_36ad4b51-a2aa-4046-83dc-f0f7bc127fa8", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 77, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_HK": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HONG KONG", "terseLabel": "Hong Kong" } } }, "localname": "HK", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_SG": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SINGAPORE", "terseLabel": "Singapore" } } }, "localname": "SG", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "country_VG": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "VIRGIN ISLANDS, BRITISH", "terseLabel": "British Virgin Island" } } }, "localname": "VG", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "currency_CNY": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "China, Yuan Renminbi", "terseLabel": "RMB", "verboseLabel": "Renminbi" } } }, "localname": "CNY", "nsuri": "http://xbrl.sec.gov/currency/2021", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r186", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r186", "r187", "r188" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r186", "r187", "r188" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]", "terseLabel": "Business Contact" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelEmailAddress": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Email address of contact personnel.", "label": "Contact Personnel Email Address" } } }, "localname": "ContactPersonnelEmailAddress", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r186", "r187", "r188" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r182" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r192" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationDateOfIncorporation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date when an entity was incorporated", "label": "Entity Incorporation, Date of Incorporation", "terseLabel": "Date of incoporation" } } }, "localname": "EntityIncorporationDateOfIncorporation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r186", "r187", "r188" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "auth_ref": [ "r19" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated other comprehensive income", "totalLabel": "Total accumulated other comprehensive income", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_AdjustedWeightedAverageShares": { "auth_ref": [ "r87" ], "lang": { "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Weighted average number of ordinary shares and potential ordinary shares used as the denominator in calculating diluted (loss)/earnings per share" } } }, "localname": "AdjustedWeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfDilutedLossearningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": { "auth_ref": [ "r96" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in inventories", "terseLabel": "Inventory" } } }, "localname": "AdjustmentsForDecreaseIncreaseInInventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "auth_ref": [ "r98" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepaid expenses", "terseLabel": "Prepaid expense and deposit" } } }, "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade accounts receivable", "terseLabel": "Accounts receivable" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "auth_ref": [ "r96" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade accounts payable", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForInterestExpense": { "auth_ref": [ "r98" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for interest expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Interest expense; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for interest expense", "terseLabel": "Interest expense" } } }, "localname": "AdjustmentsForInterestExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r97" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForUnrealisedForeignExchangeLossesGains": { "auth_ref": [ "r97", "r105" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for unrealised foreign exchange losses (gains) to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for unrealised foreign exchange losses (gains)", "terseLabel": "Foreign currency translation (gains)/losses" } } }, "localname": "AdjustmentsForUnrealisedForeignExchangeLossesGains", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r22", "r61", "r131", "r137", "r138", "r143", "r151", "r152", "r168", "r169", "r171", "r177" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity": { "auth_ref": [ "r74" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount incurred by the entity for provision of key management personnel services that are provided by a separate management entity. [Refer: Key management personnel of entity or parent [member]; Separate management entities [member]]" } }, "en-us": { "role": { "label": "Amount incurred by entity for provision of key management personnel services provided by separate management entity", "terseLabel": "Consulting fees" } } }, "localname": "AmountIncurredByEntityForProvisionOfKeyManagementPersonnelServicesProvidedBySeparateManagementEntity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "auth_ref": [ "r72", "r76" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Amounts payable, related party transactions", "terseLabel": "Related party transaction payable", "verboseLabel": "Total Related Party Payables" } } }, "localname": "AmountsPayableRelatedPartyTransactions", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r55" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable tax rate", "terseLabel": "Income tax rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r19", "r126", "r127", "r128", "r158", "r161" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "periodEndLabel": "Assets at end of period", "periodStartLabel": "Assets at beginning of period", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AverageForeignExchangeRate": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } }, "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average rate" } } }, "localname": "AverageForeignExchangeRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_BalancesWithBanks": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash balances held at banks." } }, "en-us": { "role": { "label": "Balances with banks", "terseLabel": "Cash at bank" } } }, "localname": "BalancesWithBanks", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r85", "r86" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic (loss)/earnings per share attributable to Virax", "totalLabel": "Total basic earnings (loss) per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfLossearningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_CapitalReserve": { "auth_ref": [ "r19" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the capital reserves." } }, "en-us": { "role": { "label": "Capital reserve", "verboseLabel": "Reserves" } } }, "localname": "CapitalReserve", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CapitalReserveMember": { "auth_ref": [ "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing capital reserves." } }, "en-us": { "role": { "label": "Reserves" } } }, "localname": "CapitalReserveMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "terseLabel": "Cash", "totalLabel": "Total cash" } } }, "localname": "Cash", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAdvancesAndLoansFromRelatedParties": { "auth_ref": [ "r94" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from advances and loans from related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Cash advances and loans from related parties", "terseLabel": "Proceeds from related parties" } } }, "localname": "CashAdvancesAndLoansFromRelatedParties", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r15", "r102", "r123" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at end of year", "periodStartLabel": "Cash and cash equivalents at beginning of year", "totalLabel": "Total cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CashEquivalents": { "auth_ref": [ "r102" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value." } }, "en-us": { "role": { "label": "Cash equivalents", "totalLabel": "Total cash equivalents" } } }, "localname": "CashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r92", "r104" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "netLabel": "Net cash flows from (used in) financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r92", "r104" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 0.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "netLabel": "Net cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r75" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInDeferredTaxLiabilityAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in deferred tax liability (asset) [abstract]", "terseLabel": "Deferred Tax Assets (liabilities)" } } }, "localname": "ChangesInDeferredTaxLiabilityAssetAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfInventoriesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Classes of current inventories [abstract]" } } }, "localname": "ClassesOfInventoriesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfOrdinarySharesAxis": { "auth_ref": [ "r85" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of ordinary shares [axis]" } } }, "localname": "ClassesOfOrdinarySharesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfDilutedLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "domainItemType" }, "ifrs-full_ClosingForeignExchangeRate": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } }, "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Closing rate" } } }, "localname": "ClosingForeignExchangeRate", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r3", "r38", "r107", "r109", "r117", "r120" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss35": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss36": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncome", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "auth_ref": [ "r3", "r41" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss36": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } }, "en-us": { "role": { "label": "Comprehensive income, attributable to non-controlling interests", "totalLabel": "Total comprehensive income, attributable to non-controlling interests", "verboseLabel": "Comprehensive loss attributable to non-controlling interest" } } }, "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "auth_ref": [ "r3", "r42" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss36": { "order": 0.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } }, "en-us": { "role": { "label": "Comprehensive income, attributable to owners of parent", "totalLabel": "Comprehensive loss attributable to Virax", "verboseLabel": "Comprehensive loss attributable to Virax" } } }, "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ConcentrationsOfRiskAxis": { "auth_ref": [ "r174" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Concentrations of risk [axis]" } } }, "localname": "ConcentrationsOfRiskAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ConcentrationsOfRiskMember": { "auth_ref": [ "r174" ], "lang": { "en": { "role": { "documentation": "This member stands for the concentrations of risk. It also represents the standard value for the 'Concentrations of risk' axis if no other member is used." } }, "en-us": { "role": { "label": "Concentrations of risk [member]" } } }, "localname": "ConcentrationsOfRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ConsiderationPaidReceived": { "auth_ref": [ "r101" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of consideration paid or received in respect of both obtaining and losing control of subsidiaries or other businesses. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Consideration paid (received)", "terseLabel": "Consideration paid (received)" } } }, "localname": "ConsiderationPaidReceived", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CostOfSales": { "auth_ref": [ "r2", "r48" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 1.0, "parentTag": "ifrs-full_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories." } }, "en-us": { "role": { "label": "Cost of sales", "negatedLabel": "Cost of sales", "terseLabel": "Cost of revenue" } } }, "localname": "CostOfSales", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CounterpartiesAxis": { "auth_ref": [ "r153" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Counterparties [axis]" } } }, "localname": "CounterpartiesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CounterpartiesMember": { "auth_ref": [ "r153" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } }, "en-us": { "role": { "label": "Counterparties [member]" } } }, "localname": "CounterpartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CountryOfIncorporationOrResidenceOfSubsidiary": { "auth_ref": [ "r79", "r81", "r112", "r116" ], "lang": { "en": { "role": { "documentation": "The country in which a subsidiary of the entity is incorporated. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Country of incorporation of subsidiary", "terseLabel": "Jurisdiction" } } }, "localname": "CountryOfIncorporationOrResidenceOfSubsidiary", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CreditRiskMember": { "auth_ref": [ "r144", "r172", "r173", "r174" ], "lang": { "en": { "role": { "documentation": "This member stands for the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Credit risk [member]", "terseLabel": "Credit Risk" } } }, "localname": "CreditRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrencyRiskMember": { "auth_ref": [ "r155", "r172", "r173", "r174", "r175" ], "lang": { "en": { "role": { "documentation": "This member stands for a type of market risk representing the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Currency risk [member]", "terseLabel": "Foreign Exchange Risk" } } }, "localname": "CurrencyRiskMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r23", "r117", "r118" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r25", "r117", "r119" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "negatedLabel": "Current liabilities", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "verboseLabel": "Current liabilities:" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentTradeReceivables": { "auth_ref": [ "r24", "r28" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Current trade receivables", "terseLabel": "Accounts receivable", "verboseLabel": "Current Accounts receivables" } } }, "localname": "CurrentTradeReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DateOfEndOfReportingPeriodOfFinancialStatementsOfSubsidiary": { "auth_ref": [ "r111" ], "lang": { "en": { "role": { "documentation": "The date of the end of the reporting period of the financial statements of a subsidiary." } }, "en-us": { "role": { "label": "Date of end of reporting period of financial statements of subsidiary", "terseLabel": "Incorporation Date" } } }, "localname": "DateOfEndOfReportingPeriodOfFinancialStatementsOfSubsidiary", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "dateItemType" }, "ifrs-full_DeferredTaxAssets": { "auth_ref": [ "r16", "r20", "r57" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails": { "order": 1.0, "parentTag": "ifrs-full_DeferredTaxLiabilityAsset", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Deferred tax assets", "negatedLabel": "Deferred tax assets", "terseLabel": "Deferred Tax Assets (liabilities)", "totalLabel": "Deferred Tax Assets (liabilities)" } } }, "localname": "DeferredTaxAssets", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxLiabilityAsset": { "auth_ref": [ "r57" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } }, "en-us": { "role": { "label": "Deferred tax liability (asset)", "netLabel": "Net deferred tax liability (asset)", "periodEndLabel": "Deferred tax liability (asset) at end of period", "periodStartLabel": "Deferred tax liability (asset) at beginning of period", "terseLabel": "Deferred Tax Assets (liabilities)", "totalLabel": "Net deferred tax asset (liability)" } } }, "localname": "DeferredTaxLiabilityAsset", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Employee benefits" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for fair value measurement. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for fair value measurement [text block]", "terseLabel": "Fair value hierarchy" } } }, "localname": "DescriptionOfAccountingPolicyForFairValueMeasurementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for foreign currency translation." } }, "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Foreign currency translation" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for the impairment of financial assets. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Description of accounting policy for impairment of financial assets [text block]", "terseLabel": "Impairment of assets" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfFinancialAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for income tax." } }, "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Income tax" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Leases" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "auth_ref": [ "r62" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Description of accounting policy for measuring inventories [text block]", "terseLabel": "Inventories" } } }, "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenue recognition" } } }, "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "auth_ref": [ "r10" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for segment reporting." } }, "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Segment information" } } }, "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "auth_ref": [ "r103" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpiryDateOfTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCredits": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "The description of the expiry date (if any) of deductible temporary differences, unused tax losses and unused tax credits for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Description of expiry date of deductible temporary differences, unused tax losses and unused tax credits", "terseLabel": "Expiry Date Range" } } }, "localname": "DescriptionOfExpiryDateOfTemporaryDifferencesUnusedTaxLossesAndUnusedTaxCredits", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfFunctionalCurrency": { "auth_ref": [ "r67", "r68" ], "lang": { "en": { "role": { "documentation": "The description of the currency of the primary economic environment in which the entity operates." } }, "en-us": { "role": { "label": "Description of functional currency", "terseLabel": "Functional Currency" } } }, "localname": "DescriptionOfFunctionalCurrency", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r85", "r86" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted (loss)/earnings per share attributable to Virax", "totalLabel": "Total diluted earnings (loss) per share" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfLossearningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares": { "auth_ref": [ "r87" ], "lang": { "en": { "role": { "documentation": "The number of dilutive potential ordinary shares that relate to the assumed exercise of the entity's share options." } }, "en-us": { "role": { "label": "Dilutive effect of share options on number of ordinary shares", "terseLabel": "Dilutive shares" } } }, "localname": "DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Critical Estimates and Judgments" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCriticalEstimatesAndJudgments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCashAndCashEquivalents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments." } }, "en-us": { "role": { "label": "Disclosure of commitments [text block]", "terseLabel": "Commitments" } } }, "localname": "DisclosureOfCommitmentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [abstract]" } } }, "localname": "DisclosureOfContingentLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of contingent liabilities [line items]" } } }, "localname": "DisclosureOfContingentLiabilitiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesTable": { "auth_ref": [ "r89" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to contingent liabilities." } }, "en-us": { "role": { "label": "Disclosure of contingent liabilities [table]" } } }, "localname": "DisclosureOfContingentLiabilitiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [abstract]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r130" ], "lang": { "en": { "role": { "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]" } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]", "terseLabel": "Schedule of Disaggregation of Revenue from Contracts with Customers" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "auth_ref": [ "r130" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r88" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "(Loss)/earnings per share" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "auth_ref": [ "r69" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } }, "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Disclosure of Effect of Changes in Foreign Exchange Rates" } } }, "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": { "auth_ref": [ "r52" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of events after reporting period [text block]", "terseLabel": "Subsequent Events" } } }, "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of financial assets [line items]" } } }, "localname": "DisclosureOfFinancialAssetsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "auth_ref": [ "r150" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } }, "en-us": { "role": { "label": "Disclosure of financial assets [table]" } } }, "localname": "DisclosureOfFinancialAssetsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } }, "en-us": { "role": { "label": "Disclosure of financial risk management [text block]", "terseLabel": "Risk management overview" } } }, "localname": "DisclosureOfFinancialRiskManagementExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverview" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r59" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Income tax" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTax" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Disclosure of information about key management personnel [text block]", "terseLabel": "Key management compensation" } } }, "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInventoriesExplanatory": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for inventories." } }, "en-us": { "role": { "label": "Disclosure of inventories [text block]", "terseLabel": "Inventories" } } }, "localname": "DisclosureOfInventoriesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureInventories" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [abstract]" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "auth_ref": [ "r138" ], "lang": { "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } }, "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [text block]", "terseLabel": "Schedule of Commitments for Minimum Lease Payments" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [line items]" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable": { "auth_ref": [ "r138" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis of operating lease payments." } }, "en-us": { "role": { "label": "Disclosure of maturity analysis of operating lease payments [table]" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [abstract]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [line items]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period." } }, "en-us": { "role": { "label": "Disclosure of non-adjusting events after reporting period [table]" } } }, "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNotesAndOtherExplanatoryInformationExplanatory": { "auth_ref": [ "r0" ], "lang": { "en": { "role": { "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements." } }, "en-us": { "role": { "label": "Disclosure of notes and other explanatory information [text block]", "terseLabel": "General information and reorganization transactions" } } }, "localname": "DisclosureOfNotesAndOtherExplanatoryInformationExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": { "auth_ref": [ "r90" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets." } }, "en-us": { "role": { "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]", "terseLabel": "Contingent liabilities and contingent assets" } } }, "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of reclassifications or changes in presentation [abstract]" } } }, "localname": "DisclosureOfReclassificationsOrChangesInPresentationAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of reclassifications or changes in presentation [line items]" } } }, "localname": "DisclosureOfReclassificationsOrChangesInPresentationLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationTable": { "auth_ref": [ "r12" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to reclassifications or changes in presentation." } }, "en-us": { "role": { "label": "Disclosure of reclassifications or changes in presentation [table]" } } }, "localname": "DisclosureOfReclassificationsOrChangesInPresentationTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r77" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related party transactions" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": { "auth_ref": [ "r135", "r136" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of revenue from contracts with customers [text block]", "terseLabel": "Revenue from contracts with customers" } } }, "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomers" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of risk management strategy related to hedge accounting [abstract]" } } }, "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of risk management strategy related to hedge accounting [line items]" } } }, "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable": { "auth_ref": [ "r142" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the risk management strategy in relation to hedge accounting." } }, "en-us": { "role": { "label": "Disclosure of risk management strategy related to hedge accounting [table]" } } }, "localname": "DisclosureOfRiskManagementStrategyRelatedToHedgeAccountingTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Stockholder's equity" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquity" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory": { "auth_ref": [ "r80", "r82", "r125" ], "lang": { "en": { "role": { "documentation": "The disclosure of subsidiaries. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Disclosure of subsidiaries [text block]", "terseLabel": "Summary of Consolidated Subsidiaries" } } }, "localname": "DisclosureOfSignificantInvestmentsInSubsidiariesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r11" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [abstract]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]", "terseLabel": "Summary of Temporary Differences" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [abstract]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r73" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [text block]", "terseLabel": "Summary of Related Party Payables" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r75" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share [abstract]", "verboseLabel": "Basic and diluted net loss per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r85" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Schedule of (Loss)/Earnings Per Share" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Earnings per share [line items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfDilutedLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfLossearningsPerShareDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareTable": { "auth_ref": [ "r85" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to earnings per share." } }, "en-us": { "role": { "label": "Earnings per share [table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfDilutedLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfLossearningsPerShareDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r75" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForSubsidiariesMember": { "auth_ref": [ "r80", "r82", "r125" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Subsidiaries' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for subsidiaries [member]" } } }, "localname": "EntitysTotalForSubsidiariesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r19", "r30", "r106", "r108", "r126", "r127", "r128" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Equity, ending balance", "periodStartLabel": "Equity, beginning balance", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "Equity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Stockholders' equity (deficit):" } } }, "localname": "EquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r19" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and stockholders' equity (deficit)" } } }, "localname": "EquityAndLiabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "verboseLabel": "Liabilities and stockholders' equity (deficit)" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAttributableToOwnersOfParent": { "auth_ref": [ "r18" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } }, "en-us": { "role": { "label": "Equity attributable to owners of parent", "totalLabel": "Total stockholders' equity (deficit) (Virax)" } } }, "localname": "EquityAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } }, "en-us": { "role": { "label": "Total Stockholders' Equity (Virax)" } } }, "localname": "EquityAttributableToOwnersOfParentMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_FeeAndCommissionExpense": { "auth_ref": [ "r45" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to fees and commissions." } }, "en-us": { "role": { "label": "Fee and commission expense", "negatedTotalLabel": "Total fee and commission expense", "terseLabel": "Underwriting discounts and commissions" } } }, "localname": "FeeAndCommissionExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinishedGoods": { "auth_ref": [ "r29", "r65" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of current inventory representing the amount of goods that have completed the production process and are held for sale in the ordinary course of business. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current finished goods", "terseLabel": "Finished goods" } } }, "localname": "FinishedGoods", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r9" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 2.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r60", "r133", "r166", "r179" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r60", "r133", "r166", "r179" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } }, "en-us": { "role": { "label": "Geographical areas [member]" } } }, "localname": "GeographicalAreasMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_GrossProfit": { "auth_ref": [ "r2" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]" } }, "en-us": { "role": { "label": "Gross profit", "netLabel": "Gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables": { "auth_ref": [ "r9" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of impairment loss or reversal of impairment loss recognised in profit or loss for trade receivables. [Refer: Impairment loss recognised in profit or loss; Reversal of impairment loss recognised in profit or loss; Trade receivables]" } }, "en-us": { "role": { "label": "Impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables", "netLabel": "Net impairment loss (reversal of impairment loss) recognised in profit or loss, trade receivables", "verboseLabel": "Less: provision for impairment of account receivables" } } }, "localname": "ImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossTradeReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r44", "r53", "r54", "r55", "r78", "r124", "r157" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 0.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Provision for profit tax", "negatedTerseLabel": "Income tax benefit (expense)", "terseLabel": "Provision", "totalLabel": "Total income tax expense (recovery)" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidClassifiedAsOperatingActivities": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for income taxes paid, classified as operating activities." } }, "en-us": { "role": { "label": "Income taxes paid, classified as operating activities", "terseLabel": "Income taxes" } } }, "localname": "IncomeTaxesPaidClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "auth_ref": [ "r102" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "netLabel": "Net increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "Net change in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalents", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "auth_ref": [ "r9" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Increase (decrease) in number of ordinary shares issued", "terseLabel": "Shares issued for cash, shares" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "ifrs-full_IncreaseDecreaseThroughConversionOfConvertibleInstruments": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the conversion of convertible instruments." } }, "en-us": { "role": { "label": "Increase (decrease) through conversion of convertible instruments, equity", "verboseLabel": "Shares issued for conversion of convertible debt" } } }, "localname": "IncreaseDecreaseThroughConversionOfConvertibleInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughOtherDistributionsToOwners": { "auth_ref": [ "r5" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease in equity through distributions to owners that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Settlement of fees due to a former SingaporeCo non- executive director", "negatedLabel": "Decrease through other distributions to owners, equity" } } }, "localname": "IncreaseDecreaseThroughOtherDistributionsToOwners", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransferToStatutoryReserve": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from transfers to a statutory reserve. [Refer: Statutory reserve]" } }, "en-us": { "role": { "label": "Increase (decrease) through transfer to statutory reserve, equity", "terseLabel": "Imputed interest" } } }, "localname": "IncreaseDecreaseThroughTransferToStatutoryReserve", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InformationAboutMajorCustomers": { "auth_ref": [ "r167" ], "lang": { "en": { "role": { "documentation": "Information about the entity's major customers and the extent of the entity's reliance on them." } }, "en-us": { "role": { "label": "Information about major customers", "terseLabel": "Customer information" } } }, "localname": "InformationAboutMajorCustomers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_InformationOnHowEntityDeterminedWhetherCreditRiskOfFinancialInstrumentsHasIncreasedSignificantlySinceInitialRecognition": { "auth_ref": [ "r147" ], "lang": { "en": { "role": { "documentation": "Information on how an entity determined whether the credit risk of financial instruments has increased significantly since initial recognition, including if and how: (a) financial instruments are considered to have low credit risk; and (b) the presumption that there have been significant increases in credit risk since initial recognition when financial assets are more than 30 days past due, has been rebutted. [Refer: Credit risk [member]]" } }, "en-us": { "role": { "label": "Information on how entity determined whether credit risk of financial instruments has increased significantly since initial recognition", "terseLabel": "Information on how entity determined whether credit risk of financial instruments has increased significantly since initial recognition" } } }, "localname": "InformationOnHowEntityDeterminedWhetherCreditRiskOfFinancialInstrumentsHasIncreasedSignificantlySinceInitialRecognition", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_InterestPaidClassifiedAsOperatingActivities": { "auth_ref": [ "r99" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for interest paid, classified as operating activities." } }, "en-us": { "role": { "label": "Interest paid, classified as operating activities", "negatedTerseLabel": "Interest paid" } } }, "localname": "InterestPaidClassifiedAsOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestRevenueExpense": { "auth_ref": [ "r45", "r158", "r163" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 1.0, "parentTag": "vrax_OtherIncomeExpenses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or expense arising from interest. [Refer: Interest expense; Interest income]" } }, "en-us": { "role": { "label": "Interest expense, net" } } }, "localname": "InterestRevenueExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Inventories": { "auth_ref": [ "r13", "r24", "r63" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventory, net", "totalLabel": "Inventory, net" } } }, "localname": "Inventories", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InventoryWritedown2011": { "auth_ref": [ "r47", "r64" ], "lang": { "en": { "role": { "documentation": "The amount of expense recognised related to the write-down of inventories to net realisable value. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Inventory write-down", "negatedLabel": "Inventory write down" } } }, "localname": "InventoryWritedown2011", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureInventoriesSummaryOfInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfConvertibleInstruments": { "auth_ref": [ "r6" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The change in equity resulting from the issuing of convertible instruments." } }, "en-us": { "role": { "label": "Issue of convertible instruments", "terseLabel": "Transfer of Class B to Class A", "verboseLabel": "Issue of convertible instruments" } } }, "localname": "IssueOfConvertibleInstruments", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssueOfEquity": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity through the issue of equity instruments." } }, "en-us": { "role": { "label": "Issue of equity", "terseLabel": "Shares issued for cash" } } }, "localname": "IssueOfEquity", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r30" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Issued capital", "totalLabel": "Total issued capital", "verboseLabel": "Ordinary Shares" } } }, "localname": "IssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Ordinary Shares" } } }, "localname": "IssuedCapitalMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r71" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation", "terseLabel": "Compensation award" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r70" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Share based payment" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r19", "r126", "r127", "r128", "r158", "r162" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "negatedLabel": "Liabilities", "periodEndLabel": "Liabilities at end of period", "periodStartLabel": "Liabilities at beginning of period", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MajorComponentsOfTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Major components of tax expense (income) [abstract]" } } }, "localname": "MajorComponentsOfTaxExpenseIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_MajorOrdinaryShareTransactionsMember": { "auth_ref": [ "r51" ], "lang": { "en": { "role": { "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Major ordinary share transactions [member]", "terseLabel": "Major Ordinary Share Transactions" } } }, "localname": "MajorOrdinaryShareTransactionsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r22", "r61", "r131", "r137", "r138", "r143", "r149", "r151", "r168", "r169", "r171", "r177" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MaximumExposureToCreditRisk": { "auth_ref": [ "r148", "r181" ], "lang": { "en": { "role": { "documentation": "The amount that best represents the maximum exposure to credit risk without taking into account any collateral held or other credit enhancements (for example, netting agreements that do not qualify for offset in accordance with IAS 32). [Refer: Credit risk [member]]" } }, "en-us": { "role": { "label": "Maximum exposure to credit risk", "terseLabel": "Maximum credit exposure" } } }, "localname": "MaximumExposureToCreditRisk", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncontrollingInterests": { "auth_ref": [ "r17", "r110", "r115" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Non-controlling interests", "verboseLabel": "Non-Controlling Interest" } } }, "localname": "NoncontrollingInterests", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncontrollingInterestsMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } }, "en-us": { "role": { "label": "Non Controlling Interest" } } }, "localname": "NoncontrollingInterestsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentTradeReceivables": { "auth_ref": [ "r28" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails": { "order": 0.0, "parentTag": "ifrs-full_TradeReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Non-current trade receivables", "terseLabel": "Accounts receivable" } } }, "localname": "NoncurrentTradeReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r21", "r137", "r138", "r151", "r154", "r177" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "Not later than one year [member]", "terseLabel": "Year ending March 31, 2023" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NumberOfSharesAuthorised": { "auth_ref": [ "r32" ], "lang": { "en": { "role": { "documentation": "The number of shares authorised." } }, "en-us": { "role": { "label": "Number of shares authorised", "terseLabel": "Number of shares authorised" } } }, "localname": "NumberOfSharesAuthorised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "Number of shares issued", "totalLabel": "Total number of shares issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Number of shares, ending balance", "periodStartLabel": "Number of shares, beginning balance", "terseLabel": "Number of shares outstanding" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "sharesItemType" }, "ifrs-full_OperatingExpense": { "auth_ref": [ "r45" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all operating expenses." } }, "en-us": { "role": { "label": "Operating expense", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r35", "r85" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary shares [member]" } } }, "localname": "OrdinarySharesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfDilutedLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income [abstract]", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r26", "r46" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "totalLabel": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "verboseLabel": "Foreign currency adjustment" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r33" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par value per share", "terseLabel": "Par value per share", "verboseLabel": "Par value" } } }, "localname": "ParValuePerShare", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "perShareItemType" }, "ifrs-full_PaymentsForShareIssueCosts": { "auth_ref": [ "r94" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for share issue costs." } }, "en-us": { "role": { "label": "Payments for share issue costs", "terseLabel": "Payments, fees or expenses paid, directly or indirectly, to any officers, directors or their associates, holders of 10% or more of any class of equity securities or other affiliates" } } }, "localname": "PaymentsForShareIssueCosts", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PercentageOfEntitysRevenue": { "auth_ref": [ "r167" ], "lang": { "en": { "role": { "documentation": "The percentage of the entity's revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Percentage of entity's revenue", "terseLabel": "Percenatge of revenue" } } }, "localname": "PercentageOfEntitysRevenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "auth_ref": [ "r139" ], "lang": { "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Percentage of voting equity interests acquired", "terseLabel": "Percentage of shares acquire" } } }, "localname": "PercentageOfVotingEquityInterestsAcquired", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r94" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Proceeds from issue of ordinary shares", "terseLabel": "Gross proceeds" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r93" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "Proceeds from shares issuance for cash" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProductsAndServicesAxis": { "auth_ref": [ "r132", "r164" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Products and services [axis]" } } }, "localname": "ProductsAndServicesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProductsAndServicesMember": { "auth_ref": [ "r132", "r164" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used." } }, "en-us": { "role": { "label": "Products and services [member]" } } }, "localname": "ProductsAndServicesMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r4", "r37", "r95", "r107", "r109", "r117", "r158", "r160", "r170", "r180" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 0.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 }, "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss34": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "negatedLabel": "Net loss", "terseLabel": "Net Loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "auth_ref": [ "r39", "r114" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss34": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to non-controlling interests", "negatedLabel": "Net loss attributable to non-controlling interest", "verboseLabel": "Net loss attributable to non-controlling interest" } } }, "localname": "ProfitLossAttributableToNoncontrollingInterests", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r40" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss34": { "order": 0.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 }, "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss35": { "order": 0.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to owners of parent", "terseLabel": "(Loss)/profit for the year attributable to Virax", "totalLabel": "Net loss attributable to Virax", "verboseLabel": "Net loss attributable to Virax" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r1", "r2", "r140", "r158", "r160" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails": { "order": 3.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0 }, "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Income (loss) before income taxes", "terseLabel": "Earnings (loss) for the year", "totalLabel": "Loss before income taxes" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromContinuingOperations": { "auth_ref": [ "r37", "r122", "r158", "r160" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from continuing operations", "terseLabel": "Assessable profit", "totalLabel": "Profit (loss) from continuing operations" } } }, "localname": "ProfitLossFromContinuingOperations", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r45", "r84" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 0.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating loss", "verboseLabel": "Operating loss" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": { "auth_ref": [ "r113" ], "lang": { "en": { "role": { "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]" } }, "en-us": { "role": { "label": "Proportion of ownership interests held by non-controlling interests", "terseLabel": "Ownership" } } }, "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of accounting profit multiplied by applicable tax rates [abstract]" } } }, "localname": "ReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ReductionOfIssuedCapital": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease in equity resulting from a reduction in issued capital. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Reduction of issued capital", "terseLabel": "Surrender of ViraxClear Shares" } } }, "localname": "ReductionOfIssuedCapital", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related party transactions [abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r91" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 3.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "verboseLabel": "Research & Development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r30", "r49" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings", "negatedLabel": "Accumulated deficit", "totalLabel": "Total retained earnings", "verboseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarnings", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r7", "r8" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r1", "r2", "r43", "r117", "r121", "r140", "r156", "r159", "r164", "r165", "r167" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue", "terseLabel": "Sales", "totalLabel": "Total revenue" } } }, "localname": "Revenue", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromContractsWithCustomers": { "auth_ref": [ "r129", "r130" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 0.0, "parentTag": "ifrs-full_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } }, "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenues", "verboseLabel": "Total Revenue, Net" } } }, "localname": "RevenueFromContractsWithCustomers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SellingExpense": { "auth_ref": [ "r9" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 1.0, "parentTag": "ifrs-full_OperatingExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to selling activities of the entity." } }, "en-us": { "role": { "label": "Selling expense", "verboseLabel": "Sales and Marketing" } } }, "localname": "SellingExpense", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareIssueRelatedCost": { "auth_ref": [ "r6" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cost related to the issuance of shares." } }, "en-us": { "role": { "label": "Share issue related cost", "terseLabel": "Offering expenses" } } }, "localname": "ShareIssueRelatedCost", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SignificantInvestmentsInSubsidiariesAxis": { "auth_ref": [ "r80", "r82", "r125" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Subsidiaries [axis]" } } }, "localname": "SignificantInvestmentsInSubsidiariesAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subclassifications of assets, liabilities and equities [abstract]" } } }, "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss": { "auth_ref": [ "r54" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails": { "order": 2.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to expenses not deductible in determining taxable profit (tax loss). [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect of expense not deductible in determining taxable profit (tax loss)", "terseLabel": "Change in unrecognized deductible temporary differences" } } }, "localname": "TaxEffectOfExpenseNotDeductibleInDeterminingTaxableProfitTaxLoss", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfForeignTaxRates": { "auth_ref": [ "r54" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails": { "order": 4.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect of foreign tax rates", "terseLabel": "Change in statutory, foreign tax, foreign exchange rates and other" } } }, "localname": "TaxEffectOfForeignTaxRates", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TemporaryDifferenceMember": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "This member stands for differences between the carrying amount of an asset or liability in the statement of financial position and its tax base. Temporary differences may be either: (a) taxable temporary differences; or (b) deductible temporary differences. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Temporary differences [member]", "terseLabel": "Temporary Differences" } } }, "localname": "TemporaryDifferenceMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [member]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToRelatedParties": { "auth_ref": [ "r31" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 0.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables due to related parties. [Refer: Related parties [member]; Payables to related parties]" } }, "en-us": { "role": { "label": "Current payables to related parties", "verboseLabel": "Due to related parties" } } }, "localname": "TradeAndOtherCurrentPayablesToRelatedParties", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "auth_ref": [ "r27", "r31" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "order": 0.0, "parentTag": "vrax_CurrentAccountsPayableAndAccruedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } }, "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Accounts payable" } } }, "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r14", "r28" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Owing amount", "totalLabel": "Total trade and other current receivables" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeReceivables": { "auth_ref": [ "r28" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } }, "en-us": { "role": { "label": "Trade receivables", "terseLabel": "Accounts receivable from customers", "totalLabel": "Net account receivables", "verboseLabel": "Net account receivables" } } }, "localname": "TradeReceivables", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivableSummaryOfAccountsReceivableDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TreasuryShares": { "auth_ref": [ "r30", "r83" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "An entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury shares", "negatedLabel": "Treasury shares", "terseLabel": "Treasury shares" } } }, "localname": "TreasuryShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TypesOfContractsAxis": { "auth_ref": [ "r134", "r178" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of contracts [axis]" } } }, "localname": "TypesOfContractsAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfContractsMember": { "auth_ref": [ "r134", "r178" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of contracts with customers. It also represents the standard value for the 'Types of contracts' axis if no other member is used." } }, "en-us": { "role": { "label": "Types of contracts [member]" } } }, "localname": "TypesOfContractsMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r141", "r145", "r146", "r172", "r173", "r174", "r176" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r141", "r145", "r146", "r172", "r173", "r174", "r176" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_UndiscountedOperatingLeasePaymentsToBeReceived": { "auth_ref": [ "r138" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of undiscounted operating lease payments to be received. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } }, "en-us": { "role": { "label": "Undiscounted operating lease payments to be received" } } }, "localname": "UndiscountedOperatingLeasePaymentsToBeReceived", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsScheduleOfCommitmentsForMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "auth_ref": [ "r56" ], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails": { "order": 0.0, "parentTag": "ifrs-full_DeferredTaxLiabilityAsset", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Unused tax losses for which no deferred tax asset recognised", "negatedLabel": "Unrecognized deferred tax assets", "terseLabel": "Unrecognized deferred tax asset from net operating losses", "verboseLabel": "Unrecognized deferred tax assets" } } }, "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r87" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of ordinary shares used in basic income per share", "verboseLabel": "Weighted average number of ordinary shares used as the denominator in calculating basic (ss)/earnings per share" } } }, "localname": "WeightedAverageShares", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfDilutedLossearningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average ordinary shares used in calculating basic and diluted earnings per share [abstract]", "verboseLabel": "Basic and diluted weighted average shares outstanding" } } }, "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract", "nsuri": "http://xbrl.ifrs.org/taxonomy/2021-03-24/ifrs-full", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "stringItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ChiefOperatingOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Chief Operating Officer [Member]", "terseLabel": "Chief Operating Officer" } } }, "localname": "ChiefOperatingOfficerMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesDisclosureOfEffectOfChangesInForeignExchangeRatesDetails" ], "xbrltype": "stringItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "vrax_AccountingJudgementsAndEstimatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting judgements and estimates.", "label": "Accounting Judgements And Estimates [Abstract]" } } }, "localname": "AccountingJudgementsAndEstimatesAbstract", "nsuri": "http://www.viraxbiolabs.com/20220331", "xbrltype": "stringItemType" }, "vrax_AccountsReceivableAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounts receivable.", "label": "Accounts receivable [abstract]" } } }, "localname": "AccountsReceivableAbstract", "nsuri": "http://www.viraxbiolabs.com/20220331", "xbrltype": "stringItemType" }, "vrax_AdjustmentsForGainOnDebtExtinguishment": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Adjustments for gain on debt extinguishment.", "label": "Adjustments for gain on debt extinguishment", "negatedLabel": "Gain on debt extinguishment" } } }, "localname": "AdjustmentsForGainOnDebtExtinguishment", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "vrax_AdjustmentsForIncreaseDecreaseInOperatingAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Adjustments for increase decrease in operating assets and liabilities.", "label": "Adjustments for increase decrease in operating assets and liabilities [abstract]", "terseLabel": "Net changes in operating assets & liabilities:" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOperatingAssetsAndLiabilitiesAbstract", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "vrax_AnneFosterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anne Foster.", "label": "Anne Foster [Member]", "terseLabel": "Anne Foster" } } }, "localname": "AnneFosterMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "xbrltype": "domainItemType" }, "vrax_AnneRosemaryScottFosterAnnMaryCatherineShawAlexanderTarrantShawMichaelShawAndGiuseppeCapozzoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anne rosemary scott foster ann mary catherine shaw alexander tarrant shaw michael shaw and giuseppe capozzo.", "label": "Anne Rosemary Scott Foster Ann Mary Catherine Shaw Alexander Tarrant Shaw Michael Shaw and Giuseppe Capozzo [Member]", "terseLabel": "Anne Rosemary Scott Foster Ann Mary Catherine Shaw Alexander Tarrant Shaw Michael Shaw and Giuseppe Capozzo" } } }, "localname": "AnneRosemaryScottFosterAnnMaryCatherineShawAlexanderTarrantShawMichaelShawAndGiuseppeCapozzoMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_AuthorizedShareCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Authorized share capital.", "label": "Authorized share capital", "terseLabel": "Authorized share capital" } } }, "localname": "AuthorizedShareCapital", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_BasicAndDilutedEarningLossPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basic And Diluted Earning Loss Per Share", "label": "Basic and diluted net loss per share" } } }, "localname": "BasicAndDilutedEarningLossPerShare", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "perShareItemType" }, "vrax_CameronLeeShawMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cameron Lee Shaw.", "label": "Cameron Lee Shaw [Member]", "terseLabel": "Cameron Lee Shaw" } } }, "localname": "CameronLeeShawMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "xbrltype": "domainItemType" }, "vrax_ClassAOrdinarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class a ordinary shares.", "label": "Class A Ordinary Shares [Member]", "terseLabel": "Class A Ordinary Shares" } } }, "localname": "ClassAOrdinarySharesMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_ClassASharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class A", "label": "Class A", "terseLabel": "Class A Shares" } } }, "localname": "ClassASharesMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "domainItemType" }, "vrax_ClassBOrdinarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class b ordinary shares.", "label": "Class B Ordinary Shares [Member]", "terseLabel": "Class B Ordinary Shares" } } }, "localname": "ClassBOrdinarySharesMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_ClassBOrdinarySharesToClassAOrdinarySharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class B ordinary shares to class A ordinary shares.", "label": "Class B Ordinary Shares To Class A Ordinary Shares [Member]", "terseLabel": "Class B Ordinary Shares To Class A Ordinary Shares" } } }, "localname": "ClassBOrdinarySharesToClassAOrdinarySharesMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_ClassBSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class B shares.", "label": "Class B", "terseLabel": "Class B Shares" } } }, "localname": "ClassBSharesMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "domainItemType" }, "vrax_CommitmentAndContingencies": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Commitment and contingencies.", "label": "Commitment and contingencies" } } }, "localname": "CommitmentAndContingencies", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "vrax_CommitmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commitments.", "label": "Commitments Abstract" } } }, "localname": "CommitmentsAbstract", "nsuri": "http://www.viraxbiolabs.com/20220331", "xbrltype": "stringItemType" }, "vrax_ConsultingRevenuesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Consulting revenues.", "label": "Consulting Revenues" } } }, "localname": "ConsultingRevenuesMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "domainItemType" }, "vrax_ContractualMaturitiesOfTradePayables": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contractual maturities of trade payables.", "label": "Contractual maturities of trade payables", "terseLabel": "Contractual maturities of trade payables" } } }, "localname": "ContractualMaturitiesOfTradePayables", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vrax_ConversionOfClassBOrdinarySharesInToClassAOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of class B ordinary shares in to class A ordinary shares.", "label": "Conversion of Class B Ordinary Shares In to Class A Ordinary Shares", "terseLabel": "Conversion of class B ordinary shares into class A ordinary shares" } } }, "localname": "ConversionOfClassBOrdinarySharesInToClassAOrdinaryShares", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vrax_ConversionOfClassBOrdinarySharesInToClassAOrdinarySharesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of class B ordinary shares in to class A ordinary shares description.", "label": "Conversion of Class B Ordinary Shares In to Class A Ordinary Shares Description", "terseLabel": "Conversion of class B ordinary shares into class A ordinary shares description" } } }, "localname": "ConversionOfClassBOrdinarySharesInToClassAOrdinarySharesDescription", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vrax_ConversionOfConvertibleDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of convertible debt.", "label": "Conversion of convertible debt", "terseLabel": "Conversion of convertible debt" } } }, "localname": "ConversionOfConvertibleDebt", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vrax_ConversionOfRestrictedShareUnitsForClassAShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of restricted share units for class A shares.", "label": "Conversion of Restricted Share Units for Class A shares", "terseLabel": "Conversion of restricted share units for class A shares" } } }, "localname": "ConversionOfRestrictedShareUnitsForClassAShares", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vrax_ConversionOfStockShareExchanged": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of stock share exchanged.", "label": "Conversion Of Stock Share Exchanged", "terseLabel": "Conversion of stock shares exchanged" } } }, "localname": "ConversionOfStockShareExchanged", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vrax_CourtArbitrationAwardAgainstSuppliers": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Court arbitration award against suppliers.", "label": "Court Arbitration Award Against Suppliers", "terseLabel": "Court arbitration award against supplier" } } }, "localname": "CourtArbitrationAwardAgainstSuppliers", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_CurrentAccountsPayableAndAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current accounts payable and accrued liabilities.", "label": "Current accounts payable and accrued liabilities", "terseLabel": "AP and Accrual Liabilities", "totalLabel": "Current accounts payable and accrued liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "CurrentAccountsPayableAndAccruedLiabilities", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewDisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "vrax_CurrentAccruedLiabilities": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails": { "order": 1.0, "parentTag": "vrax_CurrentAccountsPayableAndAccruedLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current accrued liabilities.", "label": "Current Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "CurrentAccruedLiabilities", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesScheduleOfAccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "vrax_CurrentPayablesToShareholder": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current payables to shareholder", "label": "Current payables to shareholder", "verboseLabel": "Due to shareholder" } } }, "localname": "CurrentPayablesToShareholder", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "vrax_CurrentPrepaidExpensesAndDeposits": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current prepaid expenses and deposits.", "label": "Current prepaid expenses and deposits", "verboseLabel": "Prepaid expenses and deposits" } } }, "localname": "CurrentPrepaidExpensesAndDeposits", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "vrax_CustomerConcentrationsRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer concentrations risk.", "label": "Customer Concentrations Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationsRiskMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_DescriptionOfAccountingPolicyForAccountsPayablesAndAccruedLiabilitiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for accounts payables and accrued liabilities.", "label": "Description Of Accounting Policy For Accounts Payables And Accrued Liabilities Explanatory", "terseLabel": "Accounts payables and accrued liabilities" } } }, "localname": "DescriptionOfAccountingPolicyForAccountsPayablesAndAccruedLiabilitiesExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vrax_DescriptionOfAccountingPolicyForAccountsReceivableExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for accounts receivable.", "label": "Description Of Accounting Policy For Accounts Receivable Explanatory", "terseLabel": "Accounts receivable" } } }, "localname": "DescriptionOfAccountingPolicyForAccountsReceivableExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vrax_DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for basis of preparation.", "label": "Description Of Accounting Policy For Basis Of Preparation Explanatory", "terseLabel": "Basis of preparation" } } }, "localname": "DescriptionOfAccountingPolicyForBasisOfPreparationExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vrax_DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for principles of consolidation.", "label": "Description Of Accounting Policy For Principles Of Consolidation Explanatory", "terseLabel": "Principles of consolidation" } } }, "localname": "DescriptionOfAccountingPolicyForPrinciplesOfConsolidationExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vrax_DescriptionOfAccountingPolicyForShareCapitalAndReservesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of accounting policy for share capital and reserves.", "label": "Description Of Accounting Policy For Share Capital And Reserves Explanatory", "terseLabel": "Share capital and reserves" } } }, "localname": "DescriptionOfAccountingPolicyForShareCapitalAndReservesExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "vrax_DilutedEarningsPerShareTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Diluted earnings per share.", "label": "Diluted Earnings Per Share [Table text block]", "terseLabel": "Schedule of Diluted (Loss)/Earnings Per Share" } } }, "localname": "DilutedEarningsPerShareTableTextBlock", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "vrax_DirectorAndChiefOperatingOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Director and Chief Operating Officer.", "label": "Director And Chief Operating Officer [Member]", "terseLabel": "Director and Chief Operating Officer" } } }, "localname": "DirectorAndChiefOperatingOfficerMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureKeyManagementCompensationAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounts payable and accrued liabilities explanatory.", "label": "Disclosure Of Accounts Payable And Accrued Liabilities Explanatory", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "DisclosureOfAccountsPayableAndAccruedLiabilitiesExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "vrax_DisclosureOfAccountsReceivableExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounts receivable.", "label": "Disclosure Of Accounts Receivable Explanatory", "terseLabel": "Accounts receivable" } } }, "localname": "DisclosureOfAccountsReceivableExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivable" ], "xbrltype": "textBlockItemType" }, "vrax_DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about accounts payable and accrued liabilities.", "label": "Disclosure Of Detailed Information About Accounts Payable And Accrued LiabilitiesExplanatory", "terseLabel": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "DisclosureOfDetailedInformationAboutAccountsPayableAndAccruedLiabilitiesexplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "vrax_DisclosureOfDetailedInformationAboutAccountsReceivableExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about accounts receivable.", "label": "Disclosure Of Detailed Information About Accounts Receivable Explanatory", "terseLabel": "Summary of Accounts Receivable" } } }, "localname": "DisclosureOfDetailedInformationAboutAccountsReceivableExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureAccountsReceivableTables" ], "xbrltype": "textBlockItemType" }, "vrax_DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about cash and cash equivalents.", "label": "Disclosure Of Detailed Information About Cash And Cash Equivalents Explanatory", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "DisclosureOfDetailedInformationAboutCashAndCashEquivalentsExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCashAndCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "vrax_DisclosureOfFunctionalAndPresentationCurrencyExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of functional and presentation currency.", "label": "Disclosure Of Functional And Presentation Currency Explanatory", "terseLabel": "Functional and Presentation Currency" } } }, "localname": "DisclosureOfFunctionalAndPresentationCurrencyExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "vrax_DisclosureOfInformationAboutInventoriesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about inventories.", "label": "Disclosure of information about inventories Explanatory", "terseLabel": "Summary of Inventories" } } }, "localname": "DisclosureOfInformationAboutInventoriesExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureInventoriesTables" ], "xbrltype": "textBlockItemType" }, "vrax_DisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of monetary assets and liabilities denominated in foreign currencies.", "label": "Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies Explanatory", "terseLabel": "Disclosure of Monetary Assets and Liabilities Denominated In Foreign Currencies" } } }, "localname": "DisclosureOfMonetaryAssetsAndLiabilitiesDenominatedInForeignCurrenciesExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewTables" ], "xbrltype": "textBlockItemType" }, "vrax_DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of net deferred tax asset liability.", "label": "Disclosure of net deferred tax asset liability [table text block]", "terseLabel": "Summary of Net Deferred Tax Asset (Liability)" } } }, "localname": "DisclosureOfNetDeferredTaxAssetLiabilityTableTextBlock", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "vrax_DisclosureOfNumberOfShareIssuedInVariousEntitiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of number of share issued in various entities.", "label": "Disclosure Of Number Of Share Issued In Various Entities Explanatory", "terseLabel": "Schedule of Number of Shares Issued" } } }, "localname": "DisclosureOfNumberOfShareIssuedInVariousEntitiesExplanatory", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsTables" ], "xbrltype": "textBlockItemType" }, "vrax_DisclosureOfReconciliationOfIncomeTaxesAtStatutoryRatesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of reconciliation of income taxes at statutory rates.", "label": "Disclosure of reconciliation of income taxes at statutory rates [Table text block]", "terseLabel": "Reconciliation of Income Taxes at Statutory Rates" } } }, "localname": "DisclosureOfReconciliationOfIncomeTaxesAtStatutoryRatesTableTextBlock", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "vrax_DueToShareHolderAndRelatedPartyPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Due to share holder and related party payable.", "label": "Due to share holder and related party payable", "terseLabel": "Due to share holder and related party payable" } } }, "localname": "DueToShareHolderAndRelatedPartyPayable", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_ExerciseOfOverallotmentOptionToPurchaseOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise of overallotment option to purchase ordinary shares.", "label": "Exercise of Overallotment Option to Purchase Ordinary Shares", "terseLabel": "Exercise of overallotment option to purchase ordinary shares" } } }, "localname": "ExerciseOfOverallotmentOptionToPurchaseOrdinaryShares", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vrax_FionaFosterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiona Foster.", "label": "Fiona Foster [Member]", "terseLabel": "Fiona Foster" } } }, "localname": "FionaFosterMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "xbrltype": "domainItemType" }, "vrax_FormerNonExecutiveDirectorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former non executive director.", "label": "Former non Executive Director [Member]", "terseLabel": "Former non-executive Director" } } }, "localname": "FormerNonExecutiveDirectorMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_HKCoIssuedSharesAfterSixTwentyFourTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HKCo issued shares after six twenty four two thousand twenty one.", "label": "H K Co Issued Shares After Six Twenty Four Two Thousand Twenty One Member", "terseLabel": "HKCo Issued Shares After 6/24/2021" } } }, "localname": "HKCoIssuedSharesAfterSixTwentyFourTwoThousandTwentyOneMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "vrax_HKCoIssuedSharesAfterStockSplitFourThirtyTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HKCo issued shares after stock split four thirty two thousand twenty one.", "label": "H K Co Issued Shares After Stock Split Four Thirty Two Thousand Twenty One [Member]", "terseLabel": "HKCo Issued shares after the stock split as of 4/30/2021" } } }, "localname": "HKCoIssuedSharesAfterStockSplitFourThirtyTwoThousandTwentyOneMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "vrax_HKCoSharesIssuedAsAtNineTwentyTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HKCo shares issued as at nine twenty two thousand twenty one.", "label": "H K Co Shares Issued As At Nine Twenty Two Thousand Twenty One [Member]", "terseLabel": "HKCo Shares issued as at 9/20/2021" } } }, "localname": "HKCoSharesIssuedAsAtNineTwentyTwoThousandTwentyOneMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "vrax_HKCoSharesIssuedForNinetyFivePointSixFiveOfSingaporeCoOnSixTwentyFourTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "HKCo shares issued for ninety five point six five of SingaporeCo on six twenty four two thousand twenty one.", "label": "H K Co Shares Issued For Ninety Five Point Six Five Of Singapore Co On Six Twenty Four Two Thousand Twenty One [Member]", "terseLabel": "HKCo shares issued for 95.65% of SingaporeCo on 6/24/2021" } } }, "localname": "HKCoSharesIssuedForNinetyFivePointSixFiveOfSingaporeCoOnSixTwentyFourTwoThousandTwentyOneMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "vrax_HkCoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hk co.", "label": "HK co [member]", "terseLabel": "HKCo" } } }, "localname": "HkCoMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_IncreaseDecreaseInNumberOfFounderShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase decrease in number of founder shares", "label": "Issuance of Founder Shares, shares" } } }, "localname": "IncreaseDecreaseInNumberOfFounderShares", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "vrax_IncreaseDecreaseInNumberOfOrdinarySharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase decrease in number of ordinary shares issued for services.", "label": "Shares issued for services, shares" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssuedForServices", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "vrax_IncreaseDecreaseInNumberOfOrdinarySharesIssuedForSettlementOfRelatedPartyPayable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase decrease in number of ordinary shares issued for settlement of related party payable.", "label": "Shares issued for settlement of related party payable, shares" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssuedForSettlementOfRelatedPartyPayable", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "vrax_IncreaseDecreaseInNumberOfOrdinarySharesIssuedToFormerNonExecutiveDirector": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Number Of Ordinary Shares Issued To Former Non executive Director", "label": "Settlement of fees due to a former SingaporeCo non- executive director, shares" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssuedToFormerNonExecutiveDirector", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "vrax_InitialPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial public offering.", "label": "Initial Public Offering [Member]", "terseLabel": "IPO" } } }, "localname": "InitialPublicOfferingMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_InvestorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investors.", "label": "Investors [Member]", "terseLabel": "Investor" } } }, "localname": "InvestorsMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_IssuanceOfFounderShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of founder shares.", "label": "Issuance of Founder Shares" } } }, "localname": "IssuanceOfFounderShares", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "vrax_IssueOfConvertibleInstrumentsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issue of convertible instruments shares.", "label": "Transfer of Class B to Class A, shares" } } }, "localname": "IssueOfConvertibleInstrumentsShares", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "vrax_IssueOfEquityForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issue of equity for services.", "label": "Shares issued for services" } } }, "localname": "IssueOfEquityForServices", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "vrax_IssueOfEquityForSettlementOfRelatedPartyPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issue of equity for settlement of related party payable.", "label": "shares", "terseLabel": "Shares issued for settlement of related party payable" } } }, "localname": "IssueOfEquityForSettlementOfRelatedPartyPayable", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "monetaryItemType" }, "vrax_IssuedShareCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issued share capital.", "label": "Issued Share Capital", "terseLabel": "Issued share capital" } } }, "localname": "IssuedShareCapital", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "vrax_JamesFosterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "James Foster.", "label": "James Foster [Member]", "terseLabel": "James Foster" } } }, "localname": "JamesFosterMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "xbrltype": "domainItemType" }, "vrax_JamesFosterTomaszGeorgeCameronShawAndMarkTernouthMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "James foster tomasz george cameron shaw and mark ternouth.", "label": "James Foster Tomasz George Cameron Shaw And Mark Ternouth [Member]", "terseLabel": "James Foster Tomasz George Cameron Shaw and Mark Ternouth" } } }, "localname": "JamesFosterTomaszGeorgeCameronShawAndMarkTernouthMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_KeyManagementCompensationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Key management compensation.", "label": "Key management compensation [abstract]" } } }, "localname": "KeyManagementCompensationAbstract", "nsuri": "http://www.viraxbiolabs.com/20220331", "xbrltype": "stringItemType" }, "vrax_LaithYakobMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Laith Yakob.", "label": "Laith Yakob [Member]", "terseLabel": "Laith Yakob" } } }, "localname": "LaithYakobMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_LeaseSecurityDeposit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lease security deposit.", "label": "Lease Security Deposit", "terseLabel": "Security deposit" } } }, "localname": "LeaseSecurityDeposit", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_LogicoBioproductCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Logico bioproduct corp.", "label": "Logico Bioproduct Corp [Member]", "terseLabel": "Logico Bioproduct Corp" } } }, "localname": "LogicoBioproductCorpMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_LogicoBioproductsCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Logico Bioproducts Corp.", "label": "Logico Bioproducts Corp [Member]", "terseLabel": "Logico Bioproducts Corp." } } }, "localname": "LogicoBioproductsCorpMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "vrax_LogicoShanghaiMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Logico Shanghai.", "label": "Logico Shanghai [Member]", "terseLabel": "Logico Shanghai" } } }, "localname": "LogicoShanghaiMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_LossesAndUnutilizedCapitalAllowancesCarriedBackPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Losses and unutilized capital allowances carried back period.", "label": "Losses and unutilized capital allowances carried back period", "terseLabel": "Losses and unutilized capital allowances carried back period" } } }, "localname": "LossesAndUnutilizedCapitalAllowancesCarriedBackPeriod", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vrax_LossesAndUnutilizedCapitalAllowancesCarriedBackSubjectToCap": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Losses and unutilized capital allowances carried back subject to cap.", "label": "Losses and unutilized capital allowances carried back subject to cap", "terseLabel": "Losses and unutilized capital allowances carried back subject to cap" } } }, "localname": "LossesAndUnutilizedCapitalAllowancesCarriedBackSubjectToCap", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_MaximumPeriodOfNetOperatingLossesCarriedForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum period of net operating losses carried forward.", "label": "Maximum period of net operating losses carried forward", "terseLabel": "Maximum period of net operating losses carried forward" } } }, "localname": "MaximumPeriodOfNetOperatingLossesCarriedForward", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vrax_MonthlyLeasePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monthly lease payment.", "label": "Monthly Lease Payment", "terseLabel": "Monthly lease payment" } } }, "localname": "MonthlyLeasePayment", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_MrIanGeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Ian Gee.", "label": "Mr Ian Gee [Member]", "terseLabel": "Mr. Ian Gee" } } }, "localname": "MrIanGeeMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_MrPatrickFosterFatherOfMrJamesFosterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Mr Patrick Foster Father Of Mr James Foster.", "label": "Mr Patrick Foster Father Of Mr James Foster [Member]", "terseLabel": "Mr. Patrick Foster, father of Mr. James Foster" } } }, "localname": "MrPatrickFosterFatherOfMrJamesFosterMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_MsAnneFosterMotherOfMrJamesFosterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ms Anne Foster mother Of Mr James Foster.", "label": "Ms Anne Foster mother Of Mr James Foster [Member]", "terseLabel": "Ms. Anne Foster, mother of Mr. James Foster" } } }, "localname": "MsAnneFosterMotherOfMrJamesFosterMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_NetProceedsFromIssueOfOrdinaryShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net proceeds from issue of ordinary shares.", "label": "Net Proceeds From Issue Of Ordinary Shares", "terseLabel": "Net proceeds" } } }, "localname": "NetProceedsFromIssueOfOrdinaryShares", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_NonCapitalLossesAvailableForFuturePeriod": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails": { "order": 0.0, "parentTag": "ifrs-full_DeferredTaxAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non capital losses available for future period.", "label": "Non Capital Losses Available For Future Period", "terseLabel": "Non-capital losses available for future period" } } }, "localname": "NonCapitalLossesAvailableForFuturePeriod", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfNetDeferredTaxAssetLiabilityDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxSummaryOfTemporaryDifferencesDetails" ], "xbrltype": "monetaryItemType" }, "vrax_NumberOfCustomer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of customer.", "label": "Number of customer" } } }, "localname": "NumberOfCustomer", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrax_NumberOfRemainingLeaseAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of remaining lease agreement.", "label": "Number of remaining lease agreement" } } }, "localname": "NumberOfRemainingLeaseAgreement", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrax_NumberOfReportableSegments1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of reportable segments1.", "label": "Number Of Reportable Segments1", "terseLabel": "Reportable segment" } } }, "localname": "NumberOfReportableSegments1", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrax_NumberOfSharesIssuedForConversionOfConvertibleDebt": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued for conversion of convertible debt.", "label": "Shares issued for conversion of convertible debt. shares" } } }, "localname": "NumberOfSharesIssuedForConversionOfConvertibleDebt", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "vrax_NumberOfSharesIssuedPerShareExchangeAgreementNineTwentyTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued per share exchange agreement nine twenty two thousand twenty one.", "label": "Number Of Shares Issued Per Share Exchange Agreement Nine Twenty Two Thousand Twenty One [Member]", "terseLabel": "Number of shares issued per Share exchange agreement 9/20/2021" } } }, "localname": "NumberOfSharesIssuedPerShareExchangeAgreementNineTwentyTwoThousandTwentyOneMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "vrax_NumberOfSharesSurrendered": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares surrendered.", "label": "Surrender of ViraxClear Shares, shares" } } }, "localname": "NumberOfSharesSurrendered", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "sharesItemType" }, "vrax_NumberOfSuppliers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of suppliers.", "label": "Number of suppliers", "terseLabel": "Number of suppliers" } } }, "localname": "NumberOfSuppliers", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "vrax_NumberOfVotesEntitled": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of votes entitled.", "label": "Number of votes entitled", "terseLabel": "Number of votes entitled" } } }, "localname": "NumberOfVotesEntitled", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "vrax_OpenTaxYears": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Open tax years", "label": "Open Tax Years", "terseLabel": "Open tax year" } } }, "localname": "OpenTaxYears", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "gYearListItemType" }, "vrax_OperatingExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating expense [abstract].", "label": "Operating expenses:" } } }, "localname": "OperatingExpenseAbstract", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "stringItemType" }, "vrax_OperatingLeaseAgreementCommencementDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease agreement commencement date.", "label": "Operating Lease Agreement Commencement Date", "terseLabel": "Operating lease agreement commencement date" } } }, "localname": "OperatingLeaseAgreementCommencementDate", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vrax_OperatingLeaseAgreementTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease agreement term.", "label": "Operating Lease Agreement Term", "terseLabel": "Operating lease agreement term" } } }, "localname": "OperatingLeaseAgreementTerm", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureCommitmentsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "vrax_OrdinarySharesClassAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares class A.", "label": "Ordinary Shares Class A", "terseLabel": "Class A", "verboseLabel": "Class A Ordinary Shares" } } }, "localname": "OrdinarySharesClassAMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfDilutedLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "domainItemType" }, "vrax_OrdinarySharesClassBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares class b.", "label": "Ordinary Shares Class B", "terseLabel": "Class B", "verboseLabel": "Class B Ordinary Shares" } } }, "localname": "OrdinarySharesClassBMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfDilutedLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureLossearningsPerShareScheduleOfLossearningsPerShareDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPositionParenthetical" ], "xbrltype": "domainItemType" }, "vrax_OrdinarySharesConversionBasis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares conversion basis.", "label": "Ordinary shares conversion basis", "terseLabel": "Ordinary shares conversion basis" } } }, "localname": "OrdinarySharesConversionBasis", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vrax_OrdinarySharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ordinary shares issued price per share.", "label": "Ordinary Shares Issued Price Per Share", "terseLabel": "Ordinary shares issued price per share" } } }, "localname": "OrdinarySharesIssuedPricePerShare", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "vrax_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationAttributableToOwnersOfParent": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss35": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other comprehensive income, net of tax, exchange differences on translation attributable to owners of parent.", "label": "Other comprehensive income, net of tax, exchange differences on translation attributable to owners of parent", "terseLabel": "Foreign currency adjustment" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslationAttributableToOwnersOfParent", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "vrax_OtherIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Income Expense [Abstract]", "label": "Other income (expense):" } } }, "localname": "OtherIncomeExpenseAbstract", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "stringItemType" }, "vrax_OtherIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 0.0, "parentTag": "vrax_OtherIncomeExpenses", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Income Expense Net", "label": "Other Income Expense Net", "verboseLabel": "Other income (expense), net" } } }, "localname": "OtherIncomeExpenseNet", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "vrax_OtherIncomeExpenses": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other Income Expenses", "label": "Other Income Expenses", "totalLabel": "Total other income (expense)" } } }, "localname": "OtherIncomeExpenses", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "monetaryItemType" }, "vrax_PatrickFosterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Patrick Foster.", "label": "Patrick Foster [Member]", "terseLabel": "Patrick Foster" } } }, "localname": "PatrickFosterMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRelatedPartyTransactionsSummaryOfRelatedPartyPayablesDetails" ], "xbrltype": "domainItemType" }, "vrax_PercentageOfCapitalOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of capital owned.", "label": "Percentage of capital owned", "terseLabel": "Percentage of capital owned" } } }, "localname": "PercentageOfCapitalOwned", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vrax_PercentageOfPurchases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of purchases.", "label": "Percentage of purchases", "terseLabel": "Percentage of purchases" } } }, "localname": "PercentageOfPurchases", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "vrax_ProceedsFromIssuingConvertibleNotePayable": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuing convertible note payable.", "label": "Proceeds from issuing convertible note payable", "terseLabel": "Proceeds from convertible note payable" } } }, "localname": "ProceedsFromIssuingConvertibleNotePayable", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "vrax_ProvisionForProfitTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Provision for profit tax.", "label": "Provision", "terseLabel": "Provision for profit tax" } } }, "localname": "ProvisionForProfitTax", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_ServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Services.", "label": "Services [Member]", "terseLabel": "Services" } } }, "localname": "ServicesMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_SettlementOfFeesDueToFormerNonExecutiveDirector": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Settlement of fees due to former non executive director.", "label": "Settlement of fees due to former non executive director", "terseLabel": "Settlement of fees due to a former SingaporeCo non-executive director" } } }, "localname": "SettlementOfFeesDueToFormerNonExecutiveDirector", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "vrax_ShanghaiXituConsultingCoLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai xitu consulting co limited.", "label": "Shanghai Xitu Consulting Co Limited [Member]", "terseLabel": "Shanghai Xitu Consulting Co., Limited" } } }, "localname": "ShanghaiXituConsultingCoLimitedMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_ShanghaiXituConsultingCoLtdFkaShanghaiLogicoBioproductsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Xitu Consulting Co Ltd FKA Shanghai Logico Bioproducts.", "label": "Shanghai Xitu Consulting Co Ltd FKA Shanghai Logico Bioproducts [Member]", "terseLabel": "Shanghai Xitu Consulting Co., Ltd (FKA- Shanghai Logico Bioproducts)" } } }, "localname": "ShanghaiXituConsultingCoLtdFkaShanghaiLogicoBioproductsMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "vrax_SharePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share price per share.", "label": "Share price per share", "terseLabel": "Share price per share" } } }, "localname": "SharePricePerShare", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "vrax_SharesIssuedForConversionOfConvertibleDebt": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares issued for conversion of convertible debt.", "label": "Shares issued for conversion of convertible debt", "terseLabel": "Shares issued for conversion of convertible debt" } } }, "localname": "SharesIssuedForConversionOfConvertibleDebt", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "vrax_SharesIssuedForSettlementOfRelatedPartyPayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Shares issued for settlement of related party payable.", "label": "Shares issued for settlement of related party payable", "terseLabel": "Shares issued for settlement of related party payable", "verboseLabel": "Shares issued for settlement of related party payable" } } }, "localname": "SharesIssuedForSettlementOfRelatedPartyPayable", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "monetaryItemType" }, "vrax_SingaporeCoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Singapore co.", "label": "Singapore Co [Member]", "terseLabel": "SingaporeCo" } } }, "localname": "SingaporeCoMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureContingentLiabilitiesAndContingentAssetsAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_SingaporeCoSharesAtThreeThirtyOneTwoThousandTwentyTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SingaporeCo shares at three thirty one two thousand twenty two.", "label": "Singapore Co Shares At Three Thirty One Two Thousand Twenty Two [Member]", "terseLabel": "SingaporeCo Shares as of 3/31/2022" } } }, "localname": "SingaporeCoSharesAtThreeThirtyOneTwoThousandTwentyTwoMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionsScheduleOfNumberOfSharesIssuedDetails" ], "xbrltype": "domainItemType" }, "vrax_SubscriptionReceivable": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Subscription receivable.", "label": "Subscription Receivable" } } }, "localname": "SubscriptionReceivable", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "vrax_SubscriptionReceivableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subscription Receivable.", "label": "Subscription", "terseLabel": "Subscription Receivable" } } }, "localname": "SubscriptionReceivableMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfChangesInEquity" ], "xbrltype": "domainItemType" }, "vrax_SubscriptionsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Subscriptions receivable.", "label": "Subscriptions receivable", "terseLabel": "Subscriptions receivable" } } }, "localname": "SubscriptionsReceivable", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_SummaryOfSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Summary of significant accounting policies.", "label": "Summary Of Significant Accounting Policies [Abstract]" } } }, "localname": "SummaryOfSignificantAccountingPoliciesAbstract", "nsuri": "http://www.viraxbiolabs.com/20220331", "xbrltype": "stringItemType" }, "vrax_SupplementalDisclosureOfCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental disclosure of cash flow information.", "label": "Supplemental disclosure of cash flow information [abstract]", "terseLabel": "Supplemental disclosure of cash flow information" } } }, "localname": "SupplementalDisclosureOfCashFlowInformationAbstract", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "vrax_SupplementalDisclosureOfNonCashInvestingAndFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplemental disclosure of non cash investing and financing activities.", "label": "Supplemental disclosure of non cash investing and financing activities [abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "SupplementalDisclosureOfNonCashInvestingAndFinancingActivitiesAbstract", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfCashFlow" ], "xbrltype": "stringItemType" }, "vrax_SupplierConcentrationOfRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier concentration of risk.", "label": "Supplier Concentration of Risk [Member]", "terseLabel": "Supplier Concentration Risk" } } }, "localname": "SupplierConcentrationOfRiskMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_SupplierInformation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Supplier information.", "label": "Supplier information", "terseLabel": "Supplier information" } } }, "localname": "SupplierInformation", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "vrax_SurrenderAmountDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Surrender amount due.", "label": "Surrender amount due", "terseLabel": "Surrender amount due" } } }, "localname": "SurrenderAmountDue", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_TaxEffectOfExpectedIncomeTaxRecovery": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails": { "order": 1.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effect of expected income tax recovery.", "label": "Tax Effect Of Expected Income Tax Recovery", "terseLabel": "Expected income tax (recovery)" } } }, "localname": "TaxEffectOfExpectedIncomeTaxRecovery", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "vrax_TaxEffectOfPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails": { "order": 0.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax effect of permanent differences.", "label": "Tax Effect Of Permanent Differences", "terseLabel": "Permanent Difference" } } }, "localname": "TaxEffectOfPermanentDifferences", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureIncomeTaxReconciliationOfIncomeTaxesAtStatutoryRatesDetails" ], "xbrltype": "monetaryItemType" }, "vrax_ThirdPartyShareholdersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third party shareholders.", "label": "Third Party Shareholders [Member]", "terseLabel": "Third Party Shareholders" } } }, "localname": "ThirdPartyShareholdersMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_ThomasBoltherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Thomas Bolther", "label": "Thomas Bolther [Member]", "terseLabel": "Thomas Bolther" } } }, "localname": "ThomasBoltherMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_TradePayablesAndAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Trade payables and accrued liabilities.", "label": "Trade payables and accrued liabilities", "terseLabel": "Trade payables and accrued liabilities" } } }, "localname": "TradePayablesAndAccruedLiabilities", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRiskManagementOverviewAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "vrax_ViraxBiolabsGroupLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virax biolabs group limited.", "label": "Virax Biolabs Group Limited [Member]", "terseLabel": "Virax Biolabs Group Limited" } } }, "localname": "ViraxBiolabsGroupLimitedMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "vrax_ViraxBiolabsHkcoLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virax biolabs hkco limited.", "label": "Virax Biolabs HKCo Limited [Member]", "terseLabel": "Virax Biolabs HKCo Limited" } } }, "localname": "ViraxBiolabsHkcoLimitedMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_ViraxBiolabsLimitedFkaShanghaiBiotechnologyDevicesLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virax Biolabs Limited FKA Shanghai Biotechnology Devices Ltd.", "label": "Virax Biolabs Limited FKA Shanghai Biotechnology Devices Ltd [Member]", "terseLabel": "Virax Biolabs Limited (FKA- Shanghai Biotechnology Devices Ltd)" } } }, "localname": "ViraxBiolabsLimitedFkaShanghaiBiotechnologyDevicesLtdMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "vrax_ViraxBiolabsLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virax biolabs limited.", "label": "Virax Biolabs Limited [Member]", "terseLabel": "Virax Biolabs Limited" } } }, "localname": "ViraxBiolabsLimitedMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_ViraxBiolabsPteLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virax biolabs pte limited.", "label": "Virax Biolabs Pte Limited [Member]", "terseLabel": "Virax Biolabs Pte. Limited" } } }, "localname": "ViraxBiolabsPteLimitedMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "vrax_ViraxBiolabsUkLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virax biolabs uk limited.", "label": "Virax Biolabs UK Limited [Member]", "terseLabel": "Virax Biolabs (UK) Limited" } } }, "localname": "ViraxBiolabsUkLimitedMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "vrax_ViraxCaymanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virax cayman.", "label": "Virax Cayman [Member]", "terseLabel": "Virax Cayman" } } }, "localname": "ViraxCaymanMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_ViraxClearAndViraxCareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virax clear and virax care.", "label": "ViraxClear and ViraxCare Revenue" } } }, "localname": "ViraxClearAndViraxCareMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureRevenueFromContractsWithCustomersScheduleOfDisaggregationOfRevenueFromContractsWithCustomersDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "domainItemType" }, "vrax_ViraxImmuneTCellMedicalDeviceCompanyLimitedFkaStorkNutritionAsiaLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virax Immune T Cell Medical Device Company Limited FKA Stork Nutrition Asia Limited.", "label": "Virax Immune T Cell Medical Device Company Limited FKA Stork Nutrition Asia Limited [Member]", "terseLabel": "Virax Immune T-Cell Medical Device Company Limited (FKA- Stork Nutrition Asia Limited)" } } }, "localname": "ViraxImmuneTCellMedicalDeviceCompanyLimitedFkaStorkNutritionAsiaLimitedMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesFunctionalAndPresentationCurrencyDetails", "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureSummaryOfSignificantAccountingPoliciesSummaryOfConsolidatedSubsidiariesDetails" ], "xbrltype": "domainItemType" }, "vrax_ViraxImmuneTCellMedicalDeviceCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Virax immune t cell medical device company limited.", "label": "Virax Immune T Cell Medical Device Company Limited [Member]", "terseLabel": "Virax Immune T- Cell Medical Device Company Limited" } } }, "localname": "ViraxImmuneTCellMedicalDeviceCompanyLimitedMember", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/DisclosureGeneralInformationAndReorganizationTransactionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "vrax_WeightedAverageOrdinarySharesUsedInCalculatingBasicAndDilutedEarningsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average ordinary shares used in calculating basic and diluted earnings per share.", "label": "Weighted average ordinary shares used in calculating basic and diluted earnings per share", "verboseLabel": "Basic and diluted weighted average shares outstanding" } } }, "localname": "WeightedAverageOrdinarySharesUsedInCalculatingBasicAndDilutedEarningsPerShare", "nsuri": "http://www.viraxbiolabs.com/20220331", "presentation": [ "http://www.viraxbiolabs.com/20220331/taxonomy/role/StatementConsolidatedStatementsOfProfitAndLossAndOtherComprehensiveLoss3" ], "xbrltype": "sharesItemType" } }, "unitCount": 11 } }, "std_ref": { "r0": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2021-03-24" }, "r1": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_102&doctype=Standard", "URIDate": "2021-03-24" }, "r10": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117_b&doctype=Standard", "URIDate": "2021-03-24" }, "r100": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35&doctype=Standard", "URIDate": "2021-03-24" }, "r101": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "40", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_40_a&doctype=Standard", "URIDate": "2021-03-24" }, "r102": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_45&doctype=Standard", "URIDate": "2021-03-24" }, "r103": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "46", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_46&doctype=Standard", "URIDate": "2021-03-24" }, "r104": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2021-03-24" }, "r105": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2021-03-24" }, "r106": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2021-03-24" }, "r107": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2021-03-24" }, "r108": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r109": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2021-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r11": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "117", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_117&doctype=Standard", "URIDate": "2021-03-24" }, "r110": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "10", "Paragraph": "22", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2021-en-r&anchor=para_22&doctype=Standard", "URIDate": "2021-03-24" }, "r111": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "11", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_11_a&doctype=Standard", "URIDate": "2021-03-24" }, "r112": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_b&doctype=Standard", "URIDate": "2021-03-24" }, "r113": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_c&doctype=Standard", "URIDate": "2021-03-24" }, "r114": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2021-03-24" }, "r115": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2021-03-24" }, "r116": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "19B", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_19B_b&doctype=Standard", "URIDate": "2021-03-24" }, "r117": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r118": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r119": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r12": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "41", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_41&doctype=Standard", "URIDate": "2021-03-24" }, "r120": { "Clause": "ix", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r121": { "Clause": "v", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r122": { "Clause": "vi", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r123": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r124": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r125": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2021-en-r&anchor=para_B4_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r126": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2021-03-24" }, "r127": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2021-03-24" }, "r128": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2021-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2021-03-24" }, "r129": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "113", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2021-03-24" }, "r13": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2021-03-24" }, "r130": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_114&doctype=Standard", "URIDate": "2021-03-24" }, "r131": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r132": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r133": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r134": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&anchor=para_B89_d&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r135": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI", "URIDate": "2021-03-24" }, "r136": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "15", "Section": "Presentation", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI", "URIDate": "2021-03-24" }, "r137": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_94&doctype=Standard", "URIDate": "2021-03-24" }, "r138": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2021-en-r&anchor=para_97&doctype=Standard", "URIDate": "2021-03-24" }, "r139": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2021-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r14": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2021-03-24" }, "r140": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r141": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2021-03-24" }, "r142": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "22A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_22A&doctype=Standard", "URIDate": "2021-03-24" }, "r143": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2021-03-24" }, "r144": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r145": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r146": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r147": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35F", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35F_a&doctype=Standard", "URIDate": "2021-03-24" }, "r148": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_35K_a&doctype=Standard", "URIDate": "2021-03-24" }, "r149": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2021-03-24" }, "r15": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2021-03-24" }, "r150": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r151": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r152": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r153": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B52", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2021-03-24" }, "r154": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r155": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "7", "Section": "Defined terms", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2021-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA_TI", "URIDate": "2021-03-24" }, "r156": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2021-03-24" }, "r157": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2021-03-24" }, "r158": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_23&doctype=Standard", "URIDate": "2021-03-24" }, "r159": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2021-03-24" }, "r16": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "o", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2021-03-24" }, "r160": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2021-03-24" }, "r161": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2021-03-24" }, "r162": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2021-03-24" }, "r163": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2021-03-24" }, "r164": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_32&doctype=Standard", "URIDate": "2021-03-24" }, "r165": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2021-03-24" }, "r166": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_33&doctype=Standard", "URIDate": "2021-03-24" }, "r167": { "IssueDate": "2021-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r168": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109&doctype=Standard", "URIDate": "2021-03-24" }, "r169": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2021-03-24" }, "r17": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "q", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2021-03-24" }, "r170": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2021-03-24" }, "r171": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_120&doctype=Standard", "URIDate": "2021-03-24" }, "r172": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_124&doctype=Standard", "URIDate": "2021-03-24" }, "r173": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_125&doctype=Standard", "URIDate": "2021-03-24" }, "r174": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_127&doctype=Standard", "URIDate": "2021-03-24" }, "r175": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r176": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2021-03-24" }, "r177": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2021-03-24" }, "r178": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_a&doctype=Standard", "URIDate": "2021-03-24" }, "r179": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2021-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2021-03-24" }, "r18": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "r", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2021-03-24" }, "r180": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2021-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2021-03-24" }, "r181": { "IssueDate": "2021-01-01", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "36", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_36_a&doctype=Standard&book=b", "URIDate": "2021-03-24" }, "r182": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r183": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r184": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r185": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r186": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r187": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r188": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r189": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r19": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_55&doctype=Standard", "URIDate": "2021-03-24" }, "r190": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r191": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r192": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_103&doctype=Standard", "URIDate": "2021-03-24" }, "r20": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "56", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_56&doctype=Standard", "URIDate": "2021-03-24" }, "r21": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2021-03-24" }, "r22": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_61&doctype=Standard", "URIDate": "2021-03-24" }, "r23": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r24": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "68", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_68&doctype=Standard", "URIDate": "2021-03-24" }, "r25": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_69&doctype=Standard", "URIDate": "2021-03-24" }, "r26": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_7&doctype=Standard", "URIDate": "2021-03-24" }, "r27": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "70", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_70&doctype=Standard", "URIDate": "2021-03-24" }, "r28": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2021-03-24" }, "r29": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_c&doctype=Standard", "URIDate": "2021-03-24" }, "r3": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2021-03-24" }, "r30": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2021-03-24" }, "r31": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_78&doctype=Standard", "URIDate": "2021-03-24" }, "r32": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r33": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r34": { "Clause": "iv", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2021-03-24" }, "r35": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2021-03-24" }, "r36": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r37": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2021-03-24" }, "r38": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2021-03-24" }, "r39": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2021-03-24" }, "r4": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2021-03-24" }, "r40": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r41": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2021-03-24" }, "r42": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r43": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2021-03-24" }, "r44": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2021-03-24" }, "r45": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_85&doctype=Standard", "URIDate": "2021-03-24" }, "r46": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2021-03-24" }, "r47": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_98_a&doctype=Standard", "URIDate": "2021-03-24" }, "r48": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_99&doctype=Standard", "URIDate": "2021-03-24" }, "r49": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2021-03-24" }, "r5": { "Clause": "iii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2021-03-24" }, "r50": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_21&doctype=Standard", "URIDate": "2021-03-24" }, "r51": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "f", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2021-03-24" }, "r52": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "10", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=10&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI", "URIDate": "2021-03-24" }, "r53": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_79&doctype=Standard", "URIDate": "2021-03-24" }, "r54": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2021-03-24" }, "r55": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r56": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2021-03-24" }, "r57": { "Clause": "i", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2021-03-24" }, "r58": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2021-03-24" }, "r59": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=12&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2021-03-24" }, "r6": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2021-03-24" }, "r60": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2021-03-24" }, "r61": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=19&code=ifrs-tx-2021-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2021-03-24" }, "r62": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2021-03-24" }, "r63": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2021-03-24" }, "r64": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_36_e&doctype=Standard", "URIDate": "2021-03-24" }, "r65": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Paragraph": "37", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&anchor=para_37&doctype=Standard", "URIDate": "2021-03-24" }, "r66": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "2", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=2&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS02_g36-39__IAS02_g36-39_TI", "URIDate": "2021-03-24" }, "r67": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "53", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_53&doctype=Standard", "URIDate": "2021-03-24" }, "r68": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Paragraph": "57", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&anchor=para_57_c&doctype=Standard", "URIDate": "2021-03-24" }, "r69": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "21", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=21&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS21_g51-57_TI", "URIDate": "2021-03-24" }, "r7": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_106&doctype=Standard", "URIDate": "2021-03-24" }, "r70": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2021-03-24" }, "r71": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r72": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r73": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18&doctype=Standard", "URIDate": "2021-03-24" }, "r74": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18A", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_18A&doctype=Standard", "URIDate": "2021-03-24" }, "r75": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_19&doctype=Standard", "URIDate": "2021-03-24" }, "r76": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r77": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=24&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS24_g13-24_TI", "URIDate": "2021-03-24" }, "r78": { "Clause": "viii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=26&code=ifrs-tx-2021-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2021-03-24" }, "r79": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r8": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_108&doctype=Standard", "URIDate": "2021-03-24" }, "r80": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2021-03-24" }, "r81": { "Clause": "ii", "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b_ii&doctype=Standard", "URIDate": "2021-03-24" }, "r82": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2021-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2021-03-24" }, "r83": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "34", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_34&doctype=Standard", "URIDate": "2021-03-24" }, "r84": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=32&code=ifrs-tx-2021-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2021-03-24" }, "r85": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_66&doctype=Standard", "URIDate": "2021-03-24" }, "r86": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_67&doctype=Standard", "URIDate": "2021-03-24" }, "r87": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2021-03-24" }, "r88": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=33&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI", "URIDate": "2021-03-24" }, "r89": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Paragraph": "86", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&anchor=para_86&doctype=Standard", "URIDate": "2021-03-24" }, "r9": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2021-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2021-03-24" }, "r90": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "37", "Section": "Disclosure", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=37&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS37_g84-92_TI", "URIDate": "2021-03-24" }, "r91": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=38&code=ifrs-tx-2021-en-r&anchor=para_126&doctype=Standard", "URIDate": "2021-03-24" }, "r92": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_10&doctype=Standard", "URIDate": "2021-03-24" }, "r93": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2021-03-24" }, "r94": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_17&doctype=Standard", "URIDate": "2021-03-24" }, "r95": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2021-03-24" }, "r96": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2021-03-24" }, "r97": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2021-03-24" }, "r98": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_20&doctype=Standard", "URIDate": "2021-03-24" }, "r99": { "IssueDate": "2021-01-01", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2021-en-r&anchor=para_31&doctype=Standard", "URIDate": "2021-03-24" } }, "version": "2.1" }